;PMID: 10671680
;source_file_741.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..34] = [t:0..34]
;1)sentence:[e:39..186] = [t:39..186]
;2)section:[e:190..248] = [t:190..248]
;3)section:[e:252..349] = [t:252..349]
;4)sentence:[e:353..542] = [t:353..542]
;5)sentence:[e:543..652] = [t:543..652]
;6)sentence:[e:654..858] = [t:654..858]
;7)sentence:[e:859..953] = [t:859..953]
;8)sentence:[e:955..1108] = [t:955..1108]
;9)section:[e:1112..1157] = [t:1112..1157]

;section 0 Span:0..34
;Oncol Rep  2000 Mar-Apr;7(2):323-6
(SEC
  (FRAG (DT:[0..5] Oncol) (NNP:[6..9] Rep) (CD:[11..15] 2000) (.:[16..19] Mar)
        (::[19..20] -) (CC:[20..26] Apr;7-LRB-) (CD:[26..27] 2)
        (-RRB-:[27..28] -RRB-) (CD:[28..32] :323) (::[32..33] -) (CD:[33..34] 6)))

;sentence 1 Span:39..186
;Mutational analysis of the CTNNB1 (beta-catenin) gene in human endometrial 
;cancer: frequent mutations at codon 34 that cause nuclear accumulation.
;[66..72]:gene-rna:"CTNNB1"
;[74..86]:gene-rna:"beta-catenin"
;[102..121]:malignancy:"endometrial  cancer"
;[132..141]:variation-event:"mutations"
;[145..153]:variation-location:"codon 34"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[39..49] Mutational) (NN:[50..58] analysis))
      (PP (IN:[59..61] of)
        (NP
          (NP (DT:[62..65] the) (NN:[66..72] CTNNB1)
            (PRN (-LRB-:[73..74] -LRB-)
              (NP (NN:[74..86] beta-catenin))
              (-RRB-:[86..87] -RRB-))
            (NN:[88..92] gene))
          (PP (IN:[93..95] in)
            (NP (JJ:[96..101] human)
               (JJ:[102..113] endometrial) (NN:[115..121] cancer))))))
    (::[121..122] :)
    (NP
      (NP
        (NP (JJ:[123..131] frequent) (NNS:[132..141] mutations))
        (PP-LOC (IN:[142..144] at)
          (NP (NN:[145..150] codon) (CD:[151..153] 34))))
      (SBAR
        (WHNP-1 (WDT:[154..158] that))
        (S
          (NP-SBJ-1 (-NONE-:[158..158] *T*))
          (VP (VBP:[159..164] cause)
            (NP (JJ:[165..172] nuclear) (NN:[173..185] accumulation))))))
    (.:[185..186] .)))

;section 2 Span:190..248
;Ikeda T, Yoshinaga K, Semba S, Kondo E, Ohmori H, Horii A.
(SEC
  (FRAG (NNP:[190..195] Ikeda) (NNP:[196..197] T) (,:[197..198] ,)
        (NNP:[199..208] Yoshinaga) (NNP:[209..210] K) (,:[210..211] ,)
        (NNP:[212..217] Semba) (NNP:[218..220] S,) (NNP:[221..226] Kondo)
        (NNP:[227..228] E) (,:[228..229] ,) (NNP:[230..236] Ohmori)
        (NNP:[237..238] H) (,:[238..239] ,) (NNP:[240..245] Horii)
        (NN:[246..248] A.)))

;section 3 Span:252..349
;Department of Molecular Pathology, Tohoku University School of Medicine,
;Sendai  980-8575, Japan.
(SEC
  (FRAG (NNP:[252..262] Department) (IN:[263..265] of)
        (NNP:[266..275] Molecular) (NNP:[276..285] Pathology) (,:[285..286] ,)
        (NNP:[287..293] Tohoku) (NNP:[294..304] University)
        (NNP:[305..311] School) (IN:[312..314] of) (NNP:[315..323] Medicine)
        (,:[323..324] ,) (NNP:[325..331] Sendai) (CD:[333..336] 980)
        (::[336..337] -) (CD:[337..341] 8575) (,:[341..342] ,)
        (NNP:[343..348] Japan) (.:[348..349] .)))

;sentence 4 Span:353..542
;Recently, CTNNB1 (beta-catenin) has been found to function as an oncoprotein 
;that works in the Wnt signaling pathway, and mutation of this gene has been 
;reported in various human cancers.
;[363..369]:gene-protein:"CTNNB1"
;[371..383]:gene-protein:"beta-catenin"
;[449..452]:gene-generic:"Wnt"
;[493..497]:gene-rna:"gene"
(SENT
  (S
    (S
      (ADVP-TMP (RB:[353..361] Recently))
      (,:[361..362] ,)
      (NP-SBJ-3 (NN:[363..369] CTNNB1)
        (PRN (-LRB-:[370..371] -LRB-)
          (NP (NN:[371..383] beta-catenin))
          (-RRB-:[383..384] -RRB-)))
      (VP (VBZ:[385..388] has)
        (VP (VBN:[389..393] been)
          (VP (VBN:[394..399] found)
            (S
              (NP-SBJ-3 (-NONE-:[399..399] *))
              (VP (TO:[400..402] to)
                (VP (VB:[403..411] function)
                  (PP-CLR (IN:[412..414] as)
                    (NP
                      (NP (DT:[415..417] an) (NN:[418..429] oncoprotein))
                      (SBAR
                        (WHNP-2 (WDT:[431..435] that))
                        (S
                          (NP-SBJ-2 (-NONE-:[435..435] *T*))
                          (VP (VBZ:[436..441] works)
                            (PP (IN:[442..444] in)
                              (NP (DT:[445..448] the) (NN:[449..452] Wnt)
                                  (NN:[453..462] signaling)
                                  (NN:[463..470] pathway)))))))))))))))
    (,:[470..471] ,) (CC:[472..475] and)
    (S
      (NP-SBJ-1
        (NP (NN:[476..484] mutation))
        (PP (IN:[485..487] of)
          (NP (DT:[488..492] this) (NN:[493..497] gene))))
      (VP (VBZ:[498..501] has)
        (VP (VBN:[502..506] been)
          (VP (VBN:[508..516] reported)
            (NP-1 (-NONE-:[516..516] *))
            (PP (IN:[517..519] in)
              (NP (JJ:[520..527] various) (JJ:[528..533] human)
                  (NNS:[534..541] cancers)))))))
    (.:[541..542] .)))

;sentence 5 Span:543..652
;In this study, we analyzed 44 endometrial  cancers and found somatic missense
;mutations in five (11%) tumors.
;[573..593]:malignancy:"endometrial  cancers"
;[612..630]:variation-type:"missense mutations"
;[645..651]:malignancy:"tumors"
(SENT
  (S
    (PP (IN:[543..545] In)
      (NP (DT:[546..550] this) (NN:[551..556] study)))
    (,:[556..557] ,)
    (NP-SBJ (PRP:[558..560] we))
    (VP
      (VP (VBD:[561..569] analyzed)
        (NP (CD:[570..572] 44)
           (JJ:[573..584] endometrial) (NNS:[586..593] cancers)))
      (CC:[594..597] and)
      (VP (VBD:[598..603] found)
        (NP (JJ:[604..611] somatic)
           (JJ:[612..620] missense) (NNS:[621..630] mutations))
        (PP-LOC (IN:[631..633] in)
          (NP (CD:[634..638] five)
            (PRN (-LRB-:[639..640] -LRB-)
              (NP (CD:[640..642] 11) (NN:[642..643] %))
              (-RRB-:[643..644] -RRB-))
            (NNS:[645..651] tumors)))))
    (.:[651..652] .)))

;sentence 6 Span:654..858
;Interestingly, four (80%) of the five tumors with mutations would cause amino
; acid alterations at residues next to Ser 33, one of the targets for 
;phosphorylation of glycogen synthase kinase (GSK)-3beta.
;[692..698]:malignancy:"tumors"
;[704..713]:variation-event:"mutations"
;[726..749]:variation-type:"amino  acid alterations"
;[753..776]:variation-location:"residues next to Ser 33"
;[821..857]:gene-protein:"glycogen synthase kinase (GSK)-3beta"
(SENT
  (S
    (ADVP (RB:[654..667] Interestingly))
    (,:[667..668] ,)
    (NP-SBJ
      (NP (CD:[669..673] four)
        (PRN (-LRB-:[674..675] -LRB-)
          (NP (CD:[675..677] 80) (NN:[677..678] %))
          (-RRB-:[678..679] -RRB-)))
      (PP (IN:[680..682] of)
        (NP
          (NP (DT:[683..686] the) (CD:[687..691] five) (NNS:[692..698] tumors))
          (PP (IN:[699..703] with)
            (NP (NNS:[704..713] mutations))))))
    (VP (MD:[714..719] would)
      (VP (VB:[720..725] cause)
        (NP
          (NML (JJ:[726..731] amino) (NN:[733..737] acid))
          (NNS:[738..749] alterations))
        (PP-LOC (IN:[750..752] at)
          (NP
            (NP (NNS:[753..761] residues))
            (ADVP-LOC (RB:[762..766] next)
              (PP (TO:[767..769] to)
                (NP
                  (NP (NN:[770..773] Ser) (CD:[774..776] 33))
                  (,:[776..777] ,)
                  (NP
                    (NP (CD:[778..781] one))
                    (PP (IN:[782..784] of)
                      (NP
                        (NP (DT:[785..788] the) (NNS:[789..796] targets))
                        (PP (IN:[797..800] for)
                          (NP
                            (NP (NN:[802..817] phosphorylation))
                            (PP (IN:[818..820] of)
                              (NP
                                (NML
                                  (NML (NN:[821..829] glycogen)
                                       (NN:[830..838] synthase)
                                       (NN:[839..845] kinase))
                                  (NML (-LRB-:[846..847] -LRB-)
                                       (NN:[847..850] GSK)
                                       (-RRB-:[850..851] -RRB-)))
                                (HYPH:[851..852] -) (NN:[852..857] 3beta)))))))))))))))
    (.:[857..858] .)))

;sentence 7 Span:859..953
;The tumors with  mutations showed accumulation of the CTNNB1 protein in
;cytoplasm and nucleus.
;[863..869]:malignancy:"tumors"
;[876..885]:variation-event:"mutations"
;[913..919]:gene-protein:"CTNNB1"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[859..862] The) (NNS:[863..869] tumors))
      (PP (IN:[870..874] with)
        (NP (NNS:[876..885] mutations))))
    (VP (VBD:[886..892] showed)
      (NP
        (NP (NN:[893..905] accumulation))
        (PP (IN:[906..908] of)
          (NP (DT:[909..912] the) (NN:[913..919] CTNNB1) (NN:[920..927] protein))))
      (PP-LOC (IN:[928..930] in)
        (NP (NN:[931..940] cytoplasm) (CC:[941..944] and)
            (NN:[945..952] nucleus))))
    (.:[952..953] .)))

;sentence 8 Span:955..1108
;This is the first report of frequent somatic mutation of the CTNNB1 gene at 
;codons adjacent to those encoding to Ser/Thr residues in endometrial cancer.
;[1000..1008]:variation-event:"mutation"
;[1016..1022]:gene-rna:"CTNNB1"
;[1089..1107]:malignancy:"endometrial cancer"
(SENT
  (S
    (NP-SBJ (DT:[955..959] This))
    (VP (VBZ:[960..962] is)
      (NP-PRD
        (NP (DT:[963..966] the) (JJ:[967..972] first) (NN:[973..979] report))
        (PP (IN:[980..982] of)
          (NP
            (NP (JJ:[983..991] frequent) (JJ:[992..999] somatic)
                (NN:[1000..1008] mutation))
            (PP (IN:[1009..1011] of)
              (NP (DT:[1012..1015] the) (NN:[1016..1022] CTNNB1)
                  (NN:[1023..1027] gene)))
            (PP-LOC (IN:[1028..1030] at)
              (NP
                (NP (NNS:[1032..1038] codons))
                (ADJP (JJ:[1039..1047] adjacent)
                  (PP (TO:[1048..1050] to)
                    (NP
                      (NP (DT:[1051..1056] those))
                      (VP (VBG:[1057..1065] encoding)
                        (PP (TO:[1066..1068] to)
                          (NP
                            (NML (NN:[1069..1072] Ser) (SYM:[1072..1073] /)
                                 (NN:[1073..1076] Thr))
                            (NNS:[1077..1085] residues)))))))))
            (PP (IN:[1086..1088] in)
              (NP (JJ:[1089..1100] endometrial) (NN:[1101..1107] cancer)))))))
    (.:[1107..1108] .)))

;section 9 Span:1112..1157
;PMID: 10671680 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1112..1116] PMID) (::[1116..1117] :) (CD:[1118..1126] 10671680)
        (NN:[1127..1128] -LSB-) (NNP:[1128..1134] PubMed) (::[1135..1136] -)
        (NN:[1137..1144] indexed) (IN:[1145..1148] for)
        (NNP:[1149..1157] MEDLINE-RSB-)))
